NAFLD Closely Tied to Diabetes Risk NAFLD Closely Tied to Diabetes Risk

Patients with non-alcoholic fatty-liver disease (NAFLD) have a higher risk of diabetes, and the more severe the disease the greater the risk, according to new research.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Gastroenterology News Source Type: news

Related Links:

Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Source Type: research
Early evidence suggests that newer diabetes drugs such as pioglitazone may improve liver enzymes and hepatic steatosis and could possibly be useful in treating non-alcoholic fatty liver disease (NAFLD), researchers say.Reuters Health Information
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Gastroenterology News Source Type: news
Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Authors: Klujszo EH, Parcheta P, Witkowska AB, Krecisz B Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity, lipid abnormalities, hypertension, and type 2 diabetes - significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis a...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Nonalcoholic fatty liver disease (NAFLD) has now become a relevant health care problem worldwide, as it affects approximately 25 –30% of adults in the general population, nearly 70% of patients with type 2 diabetes (T2DM) and almost all patients with obesity [1]. At present, the diagnosis of NAFLD is based on the following criteria: (a) hepatic steatosis on serum biomarker scores, imaging methods or histology, (b) no excess ive alcohol consumption (i.e.,
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research
Conclusions/interpretationWhen included in the standard treatment for type 2 diabetes, dulaglutide significantly reduces LFC and improves GGT levels in participants with NAFLD. There were non-significant reductions in PFC, liver stiffness, serum AST and serum ALT levels. Dulaglutide could be considered for the early treatment of NAFLD in patients with type 2 diabetes.Trial registrationClinicalTrials.gov NCT03590626FundingThe current study was supported by an investigator-initiated study grant from Medanta –The Medicity’s departmental research fund and a grant from the Endocrine and Diabetes Foundation (EDF), In...
Source: Diabetologia - Category: Endocrinology Source Type: research
CONCLUSIONS: Genetic background may affect NAFLD prognosis and ALDH2 SNP could predict the outcome. PMID: 32987175 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
More News: Alcoholism | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pathology | Urology & Nephrology